The Population Science (PS) Program's overall goal is to reduce and prevent morbidity and mortality associated with cancer and its treatment, particularly through identification of genetic and modifiable factors that may influence adverse outcomes. To address this goal, our research is focused around four themes, each of which includes research along the cancer continuum ranging from cancer etiology to cancer treatment outcomes: Nutrition and Chemoprevention;Molecular Epidemiology of Cancer Risk and Prognosis;Cancer Health Disparities;and Tobacco Epidemiology and Translation into Policy. Molecular Epidemiology and Cancer Health Disparities particularly are critical and broadly considered concepts in all themes. The Program members seek to address cancer-related problems that are important to the community that we serve, with outreach, education and interventions to reduce cancer risk and morbidity within our catchment area. The PS program is co-led by Drs. Christine Ambrosone and James Marshall, who together facilitate research in discovery, to identify genetic and environmental causes of cancer and its outcomes; prevention interventions, particularly among those at greatest risk;translation and dissemination to the community;and to ultimately impact policy, particularly related to tobacco. PS seeks to translate basic and clinical science findings to human populations, integrating basic science with cancer epidemiology. PS members include scientists with expertise in each of these areas. Program themes have matured and expanded over the last funding cycle, enhanced by receipt of a number of ROl grants supporting molecular epidemiology of cancer risk and prognosis, disparities research, including POl and U54 grants, ROl and U01-funded dietary interventions, and continued NCI and FDA support for tobacco research. The PS Program is comprised of 22 members from 7 RPCI departments (Cancer Prevention and Control, Health Behavior, Medicine, Surgical !Oncology, Urology, and Dentistry), whose total peer-reviewed funding is $17.4M (NCI funding $12M) and total funding is $22.6M. This compares favorably to $11M peer reviewed/$17M total funding at the time of the last renewal. Of the 4g9 publications generated over the last funding cycle, 28% are intra-programmatic and 15% are inter-programmatic;40 publications were in journals with an Impact Factor >10.

Public Health Relevance

The PS program conducts research to prevent cancer and its precursors, and to reduce morbidity and mortality associated with cancer and its treatment outcomes. Interventions among community and high-risk populations translate findings from the laboratory and observational studies to the community, with a focus on underserved populations in our catchment area.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016056-37
Application #
8738365
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-06-16
Project End
2019-04-30
Budget Start
2014-06-26
Budget End
2015-04-30
Support Year
37
Fiscal Year
2014
Total Cost
$39,194
Indirect Cost
$15,503
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Verma, Aparajita; Rich, Laurie J; Vincent-Chong, Vui King et al. (2018) Visualizing the effects of metformin on tumor growth, vascularity, and metabolism in head and neck cancer. J Oral Pathol Med 47:484-491
Sheffer, Christine E; Miller, Austin; Bickel, Warren K et al. (2018) The treasure of now and an uncertain future: Delay discounting and health behaviors among cancer survivors. Cancer 124:4711-4719
Nesher, Elimelech; Safina, Alfiya; Aljahdali, Ieman et al. (2018) Role of Chromatin Damage and Chromatin Trapping of FACT in Mediating the Anticancer Cytotoxicity of DNA-Binding Small-Molecule Drugs. Cancer Res 78:1431-1443
Buas, Matthew F; Li, Christopher I; Anderson, Garnet L et al. (2018) Recommendation to use exact P-values in biomarker discovery research in place of approximate P-values. Cancer Epidemiol 56:83-89
Szender, J Brian; Kaur, Jasmine; Clayback, Katherine et al. (2018) Breadth of Genetic Testing Selected by Patients at Risk of Hereditary Breast and Ovarian Cancer. Int J Gynecol Cancer 28:26-33
Azad, T; Janse van Rensburg, H J; Lightbody, E D et al. (2018) A LATS biosensor screen identifies VEGFR as a regulator of the Hippo pathway in angiogenesis. Nat Commun 9:1061
Ling, Xiang; Wu, Wenjie; Fan, Chuandong et al. (2018) An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer. J Exp Clin Cancer Res 37:240
Chung, Sejin; Vail, Paris J; Witkiewicz, Agnieszka K et al. (2018) Coordinately targeting cell cycle checkpoint functions in integrated models of pancreatic cancer. Clin Cancer Res :
Eng, Diana G; Kaverina, Natalya V; Schneider, Remington R S et al. (2018) Detection of renin lineage cell transdifferentiation to podocytes in the kidney glomerulus with dual lineage tracing. Kidney Int 93:1240-1246
Hsu, Alice H; Lum, Michelle A; Shim, Kang-Sup et al. (2018) Crosstalk between PKC? and PI3K/AKT Signaling Is Tumor Suppressive in the Endometrium. Cell Rep 24:655-669

Showing the most recent 10 out of 1555 publications